文献库搜索 | GeneLibs

Gootzen(TA),Norquist(BM),Wilke(RN),Hoppenr... Am J Obstet Gynecol 2026-06-20

...BRCA2 pathogenic variant (adjusted odds ratio 0.4 [95% confidence interval, 0.2-0.7]). In the qualitative analysis, we i...

Nelson(N),Niaz(A),Fairfax(K),Bryan(TM),Luc... Hum Mutat None

...BRCA2, TP53, TERT and ATM), when recommended thresholds were used, in silico tool predictions showed inferior sensitivit...

Della Pepa(C),Caliendo(G),Mignano(A),Zitie... Breast Care (Basel) 2026-04-15

...BRCA2 mutation after diagnosis of ovarian cancer (OC) in her sister, underwent prophylactic surgery for BC and OC, as pe...

Mehrotra(M),Chakraborty(S),Saldanha(E),Jos... J Ovarian Res 2026-06-23

...BRCA2 mutations were also observed without any association with the cisplatin-alpelisib efficacy in our cohort. Our find...

Doraczynska-Kowalik(A),Matkowski(R),Michal... J Cancer Res Clin Oncol 2026-06-23

BRCA1 and BRCA2 are key susceptibility genes in hereditary breast and ovarian cancer (HBOC), with mutational status guid...

Schnaiter(S),Santer(FR),Csanaky(KA),Jensen... Am J Hum Genet 2026-07-02

...BRCA2 wild type [BRCAwt]), 91.0% of BRCApv and 30.0% of BRCAwt tumors were HRD-GIShigh. The LR for a BRCA1 or BRCA2 vari...

Metcalfe(K),Narod(SA),Poll(A),Hoey(C),Warn... Br J Cancer 2026-06-23

...BRCA2, BRIP1, CDH1, CHEK2, PALB2, PTEN, STK11, RAD51D, RAD51C, EPCAM, MLH1, MSH2, MSH6, and PMS2). Prevalence of pathoge...

Senter(L),Hovick(S),Notestine(R),Norden(L)... Cancer Prev Res (Phila) 2026-06-24

Individuals with germline BRCA1 or BRCA2 pathogenic variants (PVs) may struggle with risk management decision-making. Ad...

Herold(N),Engel(C),Speiser(D),Ripperger(T)... Eur J Cancer 2026-08-26

...BRCA2 SH carriers were less likely to present with higher disease severity than BRCA1/BRCA2 DH carriers (BRCA1: OR 0.396...

Chen(H),Yang(W),Ying(Z),Li(A),Yang(X),Liu(... Sci Rep 2026-06-25

...BRCA2, and RAD51) in BC cells after MELK silencing. Additionally, WB was used to examine the impact of Clofibrate on the...